ClinConnect ClinConnect Logo
Search / Trial NCT02865083

The Effect of a Self-Retaining Pannus Retractor in Obese Patients Undergoing Cesarean Section

Launched by ST. LOUIS UNIVERSITY · Aug 9, 2016

Trial Information

Current as of June 03, 2025

Terminated

Keywords

ClinConnect Summary

Surgical site infections (SSI) are an important cause of morbidity following cesarean sections. The rate of surgical site infections following cesarean section in the United States is estimated between 3-15%, depending on the population studied, definitions of surgical site infection used, and length of time studied and is often underestimated. Morbidities include longer length of hospital stay, hospital readmission, wound opening and re-exploration, need for home health care, increased health care costs and loss of productivity. The risk of developing a SSI after a Cesarean section is incr...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Pregnant women with a BMI greater than or equal to 30 kg/m squared, aged 14-50 years old, undergoing non-emergent cesarean section for delivery and require pannus displacement for surgery.
  • Physicians Inclusion would include any physician who routinely perform C-sections
  • Exclusion Criteria:
  • Patients undergoing emergency Cesarean-section Pre-existing concurrent infection including chorioamnionitis State of immunosuppression (ie. HIV, cancer) Long-term steroid use (\>2 days) Patients with a BMI \<30 kg/m2, or those with a BMI \>/=30kg who do not require pannus retraction.
  • If there is a rash in the area of retraction Adhesive/tape allergy. Physicians exclusion would include any physician who does not routinely perform C-sections.

About St. Louis University

Saint Louis University (SLU) is a prestigious research institution dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong commitment to ethical research practices and collaboration across interdisciplinary teams, SLU conducts a wide range of clinical studies aimed at addressing critical health challenges. The university leverages its state-of-the-art facilities and expert faculty to facilitate groundbreaking research, ensuring that findings contribute to the development of effective therapies and enhance the overall health of diverse populations. Through its focus on community engagement and translational science, SLU fosters an environment where research translates into tangible benefits for patients and society.

Locations

Patients applied

0 patients applied

Trial Officials

Jennifer Goldkamp, MD

Principal Investigator

St. Louis University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials